CDK4 and neoplasm: Given that the presence of ER correlates with an upregulation of AR’s tumor suppressor function, trial NCT05065411 (Table 1) will target CDK4/6 to inhibit cell growth and proliferation while modulating AR’s activity to induce tumor suppression.